Tofacitinib for Covid-19 Pneumonia Patients who were hosp | UPDATES IN MEDICINE
Tofacitinib for Covid-19 Pneumonia
Patients who were hospitalized with Covid-19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group.
